Literature DB >> 30182430

Comparative pharmacokinetics of danofloxacin in healthy and Pasteurella multocida infected ducks.

Xia Xiao1,2,3, Weixuan Lan1, Ying Wang1, Lijie Jiang1, Yongjia Jiang1, Zhiqiang Wang1,2,3.   

Abstract

Pasteurella multocida (P. multocida) infection causes substantial economic loss in the duck industry. Danofloxacin, a fluoroquinolone solely used in animals, shows good antibacterial activity against P. multocida. In this study, the in vitro pharmacodynamics of danofloxacin against P. multocida was studied. The serum and lung tissue pharmacokinetics of danofloxacin were studied in healthy and P. multocida infected ducks following oral administration of a single dose of 5 mg/kg body weight (b.w.). The MIC, MBC and MPC of danofloxacin against P. multocida (C48-1 ) were 0.25, 1 and 3.2 μg/ml, respectively. The Cmax was 0.34 μg/ml, attained at 2.03 hr in healthy ducks, and was 0.35 μg/ml, attained at 2.87 hr in diseased ducks. Compared to the serum pharmacokinetics of danofloxacin in healthy ducks, the absorption rate and extent were similar in healthy and diseased animals. In contrast, the elimination rate was slower, with an elimination half-life (T1/2β ) of 13.17 and 16.18 hr for healthy and infected animals, respectively; the AUCs in the two groups were 5.70 and 7.68 μg hr/ml, respectively, which means the total amount of drug in the circulation was increased in the infected ducks. The maximum concentration in lung tissues between healthy and infected animals was not significantly different (8.96 vs. 8.93 μg/g). However, the Tmax in healthy ducks was longer than that in infected ducks (4 hr vs. 1.75 hr), which means that the distribution rate of danofloxacin was slower in healthy ducks. The concentration of danofloxacin in lung tissues was approximately 24-fold higher than that in the serum. In the serum pharmacokinetic profiles, the ƒAUC0-24 hr /MIC was 18.19 in healthy ducks and was 25.04 in P. multocida infected ducks at the clinical recommended dose, which is far from the PK/PD target (125 hr) of fluoroquinolones. Danofloxacin, at a dose of 5 mg/kg b.w., seems to be insufficient for ducks infected with P. multocida, with an MIC equal to 0.25 μg/ml.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Pasteurella multocidazzm321990; danofloxacin; ducks; infection; pharmacokinetics

Mesh:

Substances:

Year:  2018        PMID: 30182430     DOI: 10.1111/jvp.12712

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  3 in total

1.  In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks.

Authors:  Xia Xiao; Weixuan Lan; Yaqin Zhao; Ruichao Li; Yuan Liu; Juan Liu; Zhiqiang Wang
Journal:  Front Microbiol       Date:  2021-01-11       Impact factor: 5.640

2.  Optimization and Validation of Dosage Regimen for Ceftiofur against Pasteurella multocida in Swine by Physiological Based Pharmacokinetic-Pharmacodynamic Model.

Authors:  Kun Mi; Shanju Pu; Yixuan Hou; Lei Sun; Kaixiang Zhou; Wenjin Ma; Xiangyue Xu; Meixia Huo; Zhenli Liu; Changqing Xie; Wei Qu; Lingli Huang
Journal:  Int J Mol Sci       Date:  2022-03-28       Impact factor: 5.923

3.  Comparisons of plasma and fecal pharmacokinetics of danofloxacin and enrofloxacin in healthy and Mannheimia haemolytica infected calves.

Authors:  Ashenafi Feyisa Beyi; Jonathan P Mochel; Géraldine Magnin; Tyler Hawbecker; Clare Slagel; Grant Dewell; Renee Dewell; Orhan Sahin; Johann F Coetzee; Qijing Zhang; Paul J Plummer
Journal:  Sci Rep       Date:  2022-03-24       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.